Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies

Glucocorticoids are widely used for the treatment of hematological malignancies; however, their chronic use results in numerous metabolic side effects. Thus, the development of selective glucocorticoid receptor (GR) activators (SEGRA) with improved therapeutic index is important. GR regulates gene e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lesovaya, Ekaterina, Yemelyanov, Alexander, Kirsanov, Kirill, Popa, Alexander, Belitsky, Gennady, Yakubovskaya, Marianna, Gordon, Leo I., Rosen, Steven T., Budunova, Irina
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570502/
https://ncbi.nlm.nih.gov/pubmed/23255118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.23048
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars